BioWorld MedTech

Nov. 29, 2016

TAVR pioneer Edwards enters TMVR market with Valtech Cardio acquisition

Edwards Lifesciences Corp. has agreed to acquire Or Yehuda, Israel-based Valtech Cardio Ltd. for $340 million, with the potential for $350 million in additional milestone payments. Read More

Revised Cures bill, minus mandatory NIH funding, heads for 2nd House vote

GE and Boston Children's collaboration targets childhood brain diseases

FDA adds details to performance tests in endoscope safety final

Single patent system to be ratified by U.K.

Daily M&A

Financings

Other news to note

Regulatory front

Product briefs

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...